The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone
Open accessAbstract
Activation of the EGF receptors EGFR (ErbB1) and HER2 (ErbB2) drives the progression of multiple cancer types through complex mechanisms that are still not fully understood. In this study, we report that HER2 expression is elevated in bone metastases of prostate cancer independently of gene amplification. An examination of HER2 and NF-κB receptor (RANK) coexpression revealed increased levels of both proteins in aggressive prostate tumors and metastatic deposits. Inhibiting HER2 expression in bone tumor xenografts reduced proliferation and RANK expression while maintaining EGFR expression. In examining the role of EGFR in tumor-initiating cells (TIC), we found that EGFR expression was required for primary and secondary sphere formation of prostate cancer cells. EGFR expression was also observed in circulating tumor cells (CTC) during prostate cancer metastasis. Dual inhibition of HER2 and EGFR resulted in significant inhibition of tumor xenograft growth, further supporting the significance of these receptors in prostate cancer progression. Overall, our results indicate that EGFR promotes survival of prostate TIC and CTC that metastasize to bone, whereas HER2 supports the growth of prostate cancer cells once they are established at metastatic sites. Cancer Res; 77(1); 74–85. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Plaks, V., Koopman, C. D., & Werb, Z. (2013) · Science · doi:10.1126/science.1235226 · Cited by 722
Cited by
EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance
Uribe, M. L., Marrocco, I., & Yarden, Y. (2021) · Cancers · doi:10.3390/cancers13112748 · Cited by 604
GENT2: an updated gene expression database for normal and tumor tissues
Park, S.-J., Yoon, B.-H., Kim, S.-K., & Kim, S.-Y. (2019) · BMC Medical Genomics · doi:10.1186/s12920-019-0514-7 · Cited by 477
HER2 as a potential therapeutic target on quiescent prostate cancer cells
Yumoto, K., Rashid, J., Ibrahim, K. G., Zielske, S. P., Wang, Y., Omi, M., Decker, A. M., Jung, Y., Sun, D., Remmer, H. A., et al. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101642 · Cited by 11
Metadata
- Authors
- Day, K. C., Hiles, G. L., Kozminsky, M., Dawsey, S. J., Paul, A., Broses, L. J., Shah, R., Kunja, L. P., Hall, C., Palanisamy, N., Daignault-Newton, S., El-Sawy, L., Wilson, S. J., Chou, A., Ignatoski, K. W., Keller, E., Thomas, D., Nagrath, S., Morgan, T., & Day, M. L.
- Venue
- Cancer Research
- Published
- 2017-01-01
- Volume
- 77
- Issue
- 1
- Pages
- 74-85
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2545169478
- Cited by
- 183
- References
- 2
- FWCI
- 12.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone. https://app.cochat.ai/papers/10.1158/0008-5472.can-16-1656
- The paper
- Day, K. C., Hiles, G. L., Kozminsky, M., Dawsey, S. J., Paul, A., Broses, L. J., Shah, R., Kunja, L. P., Hall, C., Palanisamy, N., Daignault-Newton, S., El-Sawy, L., Wilson, S. J., Chou, A., Ignatoski, K. W., Keller, E., Thomas, D., Nagrath, S., Morgan, T., & Day, M. L. (2017). HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone. Cancer Research. https://doi.org/10.1158/0008-5472.can-16-1656
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.